---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-238059"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-05-26T12:56:06+00:00"
generated_at: "2026-05-26T13:00:18.417122+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026

## Summary
- cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.
- cORR 34.4% (11/32) in 2L cervical cancer at 3.6 mg/kg; 2 complete responses, DOR 8.0 mo.
- Safety: treatment discontinuations 2.8%; no Grade 5 events; ocular AEs manageable.
- FDA alignment on registrational trials: TEMPO-1 (OPSCC, n=250) to start summer 2026.
- 85.4% of OPSCC patients HPV+; 8 of 9 responders in OPSCC were HPV+.

## SEC filing metadata
- accession: 0001193125-26-238059
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-05-26T12:56:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/0001193125-26-238059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/crbp-20260526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-238059
- JSON: https://secwatch.observer/filing/0001193125-26-238059.json
- Plain text: https://secwatch.observer/filing/0001193125-26-238059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.